[HTML][HTML] Regulatory mechanism of icariin in cardiovascular and neurological diseases

Y Wang, C Shang, Y Zhang, L Xin, L Jiao… - Biomedicine & …, 2023 - Elsevier
Cardiovascular diseases (CVDs) and neurological diseases are widespread diseases with
substantial rates of morbidity and mortality around the world. For the past few years, the …

Optimizing management of stable angina: a patient-centered approach integrating revascularization, medical therapy, and lifestyle interventions

RA Montone, R Rinaldi, G Niccoli, G Andò… - Journal of the American …, 2024 - jacc.org
Angina pectoris may arise from obstructive coronary artery disease (CAD) or in the absence
of significant CAD (ischemia with nonobstructed coronary arteries [INOCA]). Therapeutic …

JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction

S Hokimoto, K Kaikita, S Yasuda, K Tsujita… - Circulation …, 2023 - jstage.jst.go.jp
In 2008, the Guidelines for diagnosis and treatment of patients with vasospastic angina
(coronary spastic angina) 1 were developed by the Japanese Circulation Society, and the …

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice, D D'Amario… - Cardiovascular …, 2022 - Springer
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes

F Cinti, L Leccisotti, GP Sorice, U Capece… - Cardiovascular …, 2023 - Springer
Objective We recently demonstrated that treatment with sodium-glucose cotransporter-2
inhibitors (SGLT-2i) leads to an increase in myocardial flow reserve in patients with type 2 …

[HTML][HTML] Precision medicine versus standard of care for patients with myocardial infarction with non-obstructive coronary arteries (MINOCA): rationale and design of the …

RA Montone, N Cosentino, F Graziani, R Gorla… - …, 2022 - ncbi.nlm.nih.gov
Myocardial infarction with non-obstructive coronary arteries (MINOCA) represents about 6-
8% of patients presenting with myocardial infarction (MI), and it is associated with a …

Myocardial infarction with non-obstructive coronary arteries (MINOCA)

M Yildiz, N Ashokprabhu, A Shewale, M Pico… - Frontiers in …, 2022 - frontiersin.org
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is evident in up to
15% of all acute myocardial infarctions (AMI) and disproportionally affects females. Despite …

Endothelial cell dysfunction in cardiac disease: driver or consequence?

JD Allbritton-King, G García-Cardeña - Frontiers in Cell and …, 2023 - frontiersin.org
The vascular endothelium is a multifunctional cellular system which directly influences blood
components and cells within the vessel wall in a given tissue. Importantly, this cellular …

Wildland fire, air pollution and cardiovascular health: is it time to focus on the microvasculature as a risk assessment tool?

N Naserinejad, C Costanian, O Birot, T Barboni… - Frontiers in …, 2023 - frontiersin.org
Climate change favors weather conditions conducive to wildland fires. The intensity and
frequency of forest fires are increasing, and fire seasons are lengthening. Exposure of …

Myocardial injury portends a higher risk of mortality and long-term cardiovascular sequelae after hospital discharge in COVID-19 survivors

R Rinaldi, M Basile, C Salzillo, DL Grieco… - Journal of Clinical …, 2022 - mdpi.com
Background: Cardiovascular sequelae after COVID-19 are frequent. However, the predictors
for their occurrence are still unknown. In this study, we aimed to assess whether myocardial …